Skip to Main Content

Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck

Conditions

Larynx | Lip, Oral Cavity and Pharynx

Phase II

What is the purpose of this trial?

This is a single arm Phase II study for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who are previously treated with a platinum based regimen or with an immune checkpoint inhibitor. The primary objective is to evaluate the efficacy of the combination of cetuximab and afatinib.

  • Trial with
    Yale Cancer Center
  • Start Date
    04/02/2017
  • End Date
    12/29/2019
Trial Image

For more information about this study, contact:

Tara McPartland

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/18/2020
  • Study HIC
    #1608018260